.jpg)
The pressure to move promising drug candidates into the clinic has never been greater. With growing numbers of innovative therapies entering accelerated regulatory pathways, drug developers are under increasing pressure to move efficiently from one development milestone to the next.
While oncology accounts for the largest share of accelerated approvals, the need for speed is far from limited to cancer therapies. Across therapeutic areas, companies are racing to deliver breakthrough treatments to patients faster than ever before.
Much of the industry’s focus has therefore shifted to streamlining clinical trials and reducing timelines between phases. Yet an often overlooked factor in this acceleration is the development of the drug product itself. Without clinical supplies that meet the required quality attributes, trials simply cannot begin.
In other words, clinical timelines are closely tied to how efficiently dosage forms can be developed and manufactured.
The role of development and manufacturing partners
Large pharmaceutical companies typically maintain internal development and manufacturing capabilities. However, for many smaller or emerging biotech companies, building this infrastructure is not feasible.
Without commercial revenue streams, investing in manufacturing assets represents a major financial commitment with significant risk. This is why contract development and manufacturing organizations (CDMOs) play a critical role in today’s drug development ecosystem.
CDMOs provide more than just manufacturing capacity. They bring specialized expertise across the entire development process—from formulation and process development to clinical supply manufacturing.
For smaller biotech companies, this partnership enables them to move programs forward without heavy upfront investment. For larger pharmaceutical companies, CDMOs provide flexible capacity and specialized capabilities that complement in-house operations.
Dosage form requirements evolve across development
One of the key challenges in drug product development is that requirements change significantly as a program progresses through the clinical pipeline.
Early-stage trials, particularly first-in-human studies, require only small quantities of material—often just a few hundred doses. At this stage, flexibility is critical, as dose-escalation study designs are common.
For this reason, developers often choose simple and rapidly deployable dosage forms. In some cases, the active pharmaceutical ingredient (API) can even be filled directly into capsules without additional excipients. In others, additional work may be required to improve properties such as flowability or bioavailability.
As development progresses, however, the situation quickly changes.
Later-stage trials require far larger quantities of clinical supplies, and early-stage formulations are often no longer suitable. If the ultimate commercial product will be a tablet, for example, transitioning from a simple capsule to a fully developed tablet formulation becomes necessary.
This shift introduces a much broader set of development challenges.
From simple capsules to scalable drug products
Developing a scalable dosage form involves far more than simply adjusting the amount of API.
A robust formulation requires work across multiple areas, including:
- Solid state characterization
- Analytical method development
- Excipient selection
- Stability studies
- Process development
Only once these elements are in place can manufacturing be scaled to support large pivotal clinical trials—and eventually commercial supply if the therapy is approved.
Managing this transition efficiently is essential for maintaining development momentum.A closer look at key dosage form challenges
Successfully navigating dosage form development requires balancing speed, flexibility, and long-term scalability. Decisions made very early in development can have significant downstream consequences for clinical timelines and manufacturing strategies.
Overall, thoughtful dosage form development can help drug developers move faster—without compromising the robustness required for later-stage trials and commercialization.
If you are interested in learning more about Siegfried and its capabilities, contact us:
